Among its noted accomplishments in 2010, krill oil omega-3 supplier Aker BioMarine (Aaelsund, Norway) is citing new clinical studies and Marine Stewardship Counsel Certification.
Among its noted accomplishments in 2010, krill oil omega-3 supplier Aker BioMarine (Aaelsund, Norway) is citing new clinical studies and Marine Stewardship Counsel Certification. Key milestones include:
· Two human studies published showing the superior uptake of EPA and DHA from krill oil, compared to triglyceride-sources of EPA and DHA, in the journals Lipids and Nutrition Research[1]
· A study of children with ADHD, showing significantly improved attention and objective measure of EEG activity[2]
· A published study elucidating 69 distinct phospholipids in the composition of krill, providing insight for the identification of krill ingredients, future research, and product development, in Lipids[3]
· A study showing significant improvements in arthritis symptoms in a mouse model in the journal BMC Musculoskeletal Disorders[4]
· The award of Marine Stewardship Counsel Certification (MSC), a first for krill harvesting based upon sustainable practices and traceability[5]
· Commercial and trade recognition, including the Professors of Pharmacy Award in Europe and leading trends recognition for the krill supplements category by Whole Foods and other magazines[6]
According to Matts Johansen, vice president of sales and marketing, “Aker BioMarine is committed to best practices in harvesting and production of krill products, from our eco-friendly harvesting to our commitment to promote research in Antarctic species aboard our vessel. Our MSC certification and 100% utilization of catch demonstrates our commitment to conservation. And our investment in research to substantiate claims and discover new human health benefits also demonstrates our commitment to support industry and to deliver upon the promise of krill for consumers.”
“Superba Krill provides the essential fatty acids EPA and DHA in the phospholipid form, providing the most bio-efficient and tolerable delivery of these vital omega-3's,” states Johansen. “This efficient phospholipid source provides significant consumer advantages, allowing consumers to use a smaller, easier to swallow capsule, and the phospholipid-bound EPA and DHA are free of fishy aftertaste and oily burps. Plus, Krill is a sustainable source.”
References:
[1] http://www.springerlink.com/content/270j241473471664 "Metabolic Effects of Krill Oil are Essentially Similar to Those of Fish Oil but at Lower Dose of EPA and DHA, in Healthy Volunteers," and http://www.nrjournal.com/article/S0271-5317(09)00161-4/abstract "Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women"
[2] (manuscript in preparation)
[3] http://www.springerlink.com/content/0g23u26438410262 "Elucidation of Phosphatidylcholine Composition in Krill Oil Extracted from Euphausia superba"
[4] http://www.biomedcentral.com/1471-2474/11/136 "Supplementation of diet with krill oil protects against experimental rheumatoid arthritis"
[5] http://www.msc.org/track-a-fishery/certified/southern-ocean/aker-biomarine-antarctic-krill
[6] http://www.wholefoodsmagazineonline.com/supplements/features/omegas-update-reactions-years-hottest-headlines-part 1; http://www.wholefoodsmagazineonline.com/supplements/features/omega-update-reactions-years-hottest-headlines-part 2
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.